CD133 may be a potential prognostic marker and useful therapeutic target in lung cancer, and co-detection of CD133 with other CSC markers including ALDH1A1 and OCT4 may be more valuable and helpful in clinical application in NSCLC patients. Here, PROM1 is linked to non-small cell lung carcinoma.